Catalyst Funds Management Pty Ltd Makes New Investment in Black Diamond Therapeutics, Inc. $BDTX

Catalyst Funds Management Pty Ltd bought a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,500 shares of the company’s stock, valued at approximately $46,000.

Other institutional investors also recently modified their holdings of the company. R Squared Ltd bought a new position in Black Diamond Therapeutics in the 2nd quarter worth approximately $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Black Diamond Therapeutics during the second quarter worth $28,000. Y Intercept Hong Kong Ltd bought a new position in shares of Black Diamond Therapeutics in the second quarter worth $36,000. CWM LLC boosted its holdings in shares of Black Diamond Therapeutics by 212.2% in the second quarter. CWM LLC now owns 14,338 shares of the company’s stock worth $36,000 after acquiring an additional 9,746 shares during the period. Finally, Bailard Inc. purchased a new position in shares of Black Diamond Therapeutics in the second quarter valued at $39,000. 95.47% of the stock is currently owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Trading Down 0.3%

Shares of NASDAQ BDTX opened at $3.80 on Friday. The business has a 50-day moving average of $3.83 and a 200-day moving average of $3.01. The firm has a market capitalization of $216.49 million, a price-to-earnings ratio of 10.56 and a beta of 3.12. Black Diamond Therapeutics, Inc. has a 12 month low of $1.20 and a 12 month high of $4.94.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts predict that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BDTX has been the topic of a number of recent research reports. Wall Street Zen cut Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Black Diamond Therapeutics in a report on Tuesday. Guggenheim initiated coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of Black Diamond Therapeutics in a report on Wednesday, October 15th. They set a “buy” rating and a $8.00 target price on the stock. Finally, HC Wainwright lowered their target price on shares of Black Diamond Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.50.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.